Alexamorelin
PMID 11022186 reports that Alexamorelin produced the same dose-dependent growth hormone increase as Hexarelin in six young adults (checked 2026-08-26). It also produced the same dose-dependent prolactin increase. PubMed tags the paper as Research Support, Non-U.S. Gov't. PubMed names no grant or funder. Crossref lists no funder. This was a hormone-response test. It did not track long-term health.
What exactly is Alexamorelin?
Alexamorelin is a synthetic heptapeptide growth hormone secretagogue. The direct human paper uses ALEX as a study shorthand. The register stores no alias for it.
| Identity field | Verified value |
|---|---|
| Register name | Alexamorelin |
| Register class | Synthetic heptapeptide growth hormone secretagogue (PMID 11022186; checked 2026-08-26) |
| Register aliases | None stored |
| Study shorthand | ALEX; not a stored register alias |
| Peptide sequence | Ala-His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 (PMID 11022186; checked 2026-08-26) |
| PubChem CID | 10011122, checked 2026-08-26 |
| PubChem CAS | 196808-85-2, checked 2026-08-26 |
| Molecular formula | C50H63N13O7, PubChem, checked 2026-08-26 |
| Molecular weight | 958.1, PubChem, checked 2026-08-26 |
| InChIKey | PVMNKVLENCIGRW-ANFQCQCRSA-N, PubChem, checked 2026-08-26 |
| Register identifier block | None stored |
| GSRS exact-name result | No Alexamorelin record; checked 2026-08-26 |
| GSRS exact-sequence result | No matching record; checked 2026-08-26 |
| Related register record | Hexarelin, the comparator in PMID 11022186 |
Both GSRS checks had working controls. The exact Hexarelin query returned one record. The exact Ipamorelin query returned two records.
What did the human study measure?
The paper tested Alexamorelin and Hexarelin in six young adults. It measured short hormone responses.
| Human record | Measured finding | Funding and limit |
|---|---|---|
| PMID 11022186 | Alexamorelin and Hexarelin produced the same dose-dependent GH increase. They also produced the same dose-dependent prolactin increase. Both compounds produced dose-dependent ACTH increases. Both compounds produced dose-dependent cortisol increases. The highest tested Alexamorelin level produced a significantly higher ACTH response than Hexarelin. It also produced a significantly higher cortisol response than Hexarelin. Aldosterone rose significantly after both tested intravenous Alexamorelin levels. It did not rise after Hexarelin. The oral GH response to Alexamorelin was higher than the Hexarelin response, but the difference was not significant. | PubMed classifies the paper as Research Support, Non-U.S. Gov't. PubMed names no grant or funder. Crossref lists no funder. The PubMed affiliation is the University of Turin. This was a short response study. The opened abstract gives no adverse-event count or rate. Checked 2026-08-26. |
How strong is the evidence?
Evidence tier B marks the six-person human study (checked 2026-08-26). PMID 11022186 measured hormone responses. It did not track long-term health.
What do current United States product records show?
| Exact search checked August 26, 2026 | Result | Boundary |
|---|---|---|
DailyMed: Alexamorelin | No current label | Exact name only |
openFDA Drugs@FDA: Alexamorelin | No matching application | Does not settle another name, place, or time |
What do the central EU and country fields show?
| Field | Current primary record |
|---|---|
Central EU status: unclear | The EMA report generated August 26, 2026 contains 2,732 medicine rows. No row contains Alexamorelin, 196808-85-2, or the full sequence. Positive controls resolved. The central file does not cover every national authorization. |
Germany: unclear | Alexamorelin is not printed among the named examples in the current DmMV annex. The GHS and GHRP category lists are introduced as examples. Nonappearance therefore does not prove that either category excludes Alexamorelin. The register applies neither category here. Checked 2026-08-26. |
Sweden: unclear | The product file dated August 26, 2026 contains 38,382 rows. No row contains Alexamorelin, 196808-85-2, or the full sequence. Positive controls resolved. This exact-term result does not settle classification under another name. |
Status and evidence tier answer different questions.
When was Alexamorelin first observed in the register?
The register stores first_observed: 2011-02.
PMID 21298258 was published online on February 6, 2011 (checked 2026-08-26). It names Alexamorelin in a urine-test method. This date marks an assay being built. It does not mark a seized vial. It does not mark a product for sale. It does not mark a purchase.
What does the large submitted-vial study show?
| Submitted-vial paper | Alexamorelin result |
|---|---|
| 2026 preprint, DOI 10.20944/preprints202604.1748.v1 | The paper lists fourteen tested compounds. Alexamorelin is not one of them. It supplies no Alexamorelin identity result. It supplies no Alexamorelin amount result. It supplies no Alexamorelin purity result. It supplies no Alexamorelin endotoxin result. Checked 2026-08-26. |
This list does not prove a wider absence.